Maxim upgraded CNS Pharmaceuticals to Buy from Hold with a 50c price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNSP:
- CNS Pharmaceuticals sees cash runway through 1Q25
- CNS Pharmaceuticals reports Q2 EPS ($6.72) vs. ($51.86) last year
- Biotech Alert: Searches spiking for these stocks today
- CNS Pharmaceuticals Expands Portfolio with Strategic Licensing Deal
- CNS Pharmaceuticals enters license agreement with Cortice Biosciences